Alembic Pharma shares rise on USFDA nod for prostate cancer drug with $3 billion estimated market size

Alembic Pharmaceuticals shares gained after USFDA granted a tentative ANDA nod for Darolutamide Tablets 300 mg, a prostate cancer drug, marking its 238th ANDA approval.

Leave a Reply

Your email address will not be published. Required fields are marked *